GlassScriptPhysician profile
Brian J Mcneel
NPI 1821094152
$5,567.66
in general payments reported to CMS, 2019-2025
21 companies · $699 in 2025
The $699 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $242 · 2021: $962 · 2022: $912 · 2023: $904 · 2024: $462 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.81 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,002.71 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Novartis Pharmaceuticals Corporation | $945.13 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $628.77 | 2021-2024 | Atlas Corneal Topography System, Clarus |
| Bausch & Lomb Americas INC. | $626.33 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Carl Zeiss Meditec, INC. | $333.77 | 2019 | |
| Kala Pharmaceuticals, INC. | $227.49 | 2021-2022 | |
| Sight Sciences, INC. | $217.56 | 2021-2023 | Tearcare System |
| Johnson & Johnson Vision Care, INC. | $204.46 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $202.39 | 2024-2025 | Xdemvy |
| Abbvie INC. | $160.77 | 2022-2025 | |
| Shire North American Group INC | $141.99 | 2019 | |
| Coopervision INC. | $141.38 | 2025 | Myday Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $132.41 | 2019-2024 | Cequa |
| Aerie Pharmaceuticals, INC. | $114.10 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $111.82 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $93.17 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.28 | 2019 | |
| Heru, INC. | $77.04 | 2022 | |
| Dompe US, INC. | $70.66 | 2024-2025 | Oxervate |
| Abb Con-Cise Optical Group LLC | $31.98 | 2019 | |
| Allergan, INC. | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Mcneel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.